Phaseline

Targets › CYP3A43

CYP3A43 (Cytochrome P450 3A43): drug programs, companies and trials

7 programs from 7 companies in 9 trials: 3 Phase 2, 2 Phase 1, 2 Phase 3, 2 Phase 4; Infectious disease, Oncology; next expected readout Jan 2027.

A cytochrome P450 monooxygenase involved in the metabolism of xenobiotics such as the psychoactive drugs olanzapine and alprazolam. May be involved in the metabolism of endogenous compounds, although the range of substrates remain largely uncharacterized (Probable). (UniProt, Q9HB55)

Open in Phaseline: the race on CYP3A43, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mount Sinai Hospital, CanadaRitonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 4SARS CoV-2 Post-Acute SequelaeJan 2027
Gilead SciencesCobicistat
Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 4HIV-1-infection; AML, AdultJun 2027
University of OxfordRitonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 3Pneumonia; COVID-19Jan 2027
Haukeland University HospitalRitonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 3Post COVID-19 Condition, UnspecifiedJun 2027
Harvard School of Public Health (HSPH)Ritonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 2HIVJun 2029
University of Wisconsin, MadisonRitonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 1High-Grade Anal Intraepithelial NeoplasiaJun 2027
University of MiamiRitonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 1High Grade GliomaApr 2029

Conditions

HIV (1) High-Grade Anal Intraepithelial Neoplasia (1) Post COVID-19 Condition, Unspecified (1) SARS CoV-2 Post-Acute Sequelae (1) Pneumonia (1) COVID-19 (1) HIV-1-infection (1) AML, Adult (1) High Grade Glioma (1)

Modalities

small molecule (5), mixed (2)

Companies

Harvard School of Public Health (HSPH) (1) University of Wisconsin, Madison (1) Haukeland University Hospital (1) Mount Sinai Hospital, Canada (1) University of Oxford (1) Gilead Sciences (1) University of Miami (1)

Related targets

CYP3A4 (7) CYP3A5 (7) CYP3A7 (7)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.